Misoprostol: preventing postpartum haemorrhage.
Postpartum haemorrhage is an important cause of maternal mortality and morbidity. In the developing world, it is estimated to account for 28% of maternal deaths. Evidence suggests that active management of the third stage of labour using oxytocics, significantly reduces the risk of PPH. Oxytocics are not always used in the developing world, due to storage problems, mode of administration and associated side-effects. Research using misoprostol, a prostaglandin, suggests that it may be effective in the prevention of PPH. It is given orally, does not require refrigeration and has few side-effects. Further research is planned, if misoprostol is found to be an acceptable alternative to other oxytocic agents, then it may be instrumental in reducing world wide deaths from PPH.
Walder
J
J
Delivery Suite, John Radcliffe Hospital, Oxford.
D003906:Developing Countries; D005260:Female; D014943:Global Health; D006801:Humans; D016595:Misoprostol / Q000627:therapeutic use*; D010120:Oxytocics / Q000627:therapeutic use*; D006473:Postpartum Hemorrhage / Q000188:drug therapy* / Q000517:prevention & control; D011247:Pregnancy; D006113:United Kingdom
D010120:Oxytocics; D016595:Misoprostol